103633-30-3

Basic information

• Product Name: 2-BENZYLOXYBENZYLBROMIDE
• Synonyms: Benzene, 1-(broMoMethyl)-2-(phenylMethoxy)-;1-(benzyloxyMethyl)-2-(broMoMethyl)benzene;2-BENZYLOXYBENZYLBROMIDE
• CAS NO: 103633-30-3
• Molecular Formula: C₁₄H₁₃BrO
• Molecular Weight: 277.16
• Product Categories: pharmacetical
• Mol File: 103633-30-3.mol

Chemical Properties

• Melting Point: 40-42 °C
• Boiling Point: 354.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.361±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-BENZYLOXYBENZYLBROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYLOXYBENZYLBROMIDE(103633-30-3)
• EPA Substance Registry System: 2-BENZYLOXYBENZYLBROMIDE(103633-30-3)

Safety Data

• Hazardous Substances Data: 103633-30-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Benzyloxybenzylbromide is used as a reagent in the organic synthesis of pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and medications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Benzyloxybenzylbromide is employed as a key intermediate for the synthesis of various organic compounds. Its versatility and reactivity contribute to the creation of a wide range of chemical products, including those with potential applications in different industries.
Used in Research and Development:
2-Benzyloxybenzylbromide is also utilized in research and development settings to explore its potential applications and properties. Scientists and researchers use this compound to investigate new chemical reactions, mechanisms, and pathways, further expanding the knowledge and understanding of organic chemistry.

Upstream product

• 100-39-0 benzyl bromide 
• 90-02-8 salicylaldehyde 
• 100-44-7 benzyl chloride 
• 5896-17-3 2-(phenylmethoxy)benzaldehyde 
• 90-01-7 salicylic alcohol 
• 89-95-2 2-methyl-benzyl alcohol 
• 3381-87-1 2-benzyloxybenzyl alcohol 

Downstream Products

• 212116-74-0 (Z)-2,3'-dibenzyloxy-4',5'-dimethoxystilbene 
• 212116-75-1 (E)-2,3'-dibenzyloxy-4',5'-dimethoxystilbene 
• 1209470-16-5 C₃₆H₃₂O₆ 
• 1209470-18-7 4',6'-bis[2-(benzyloxy)benzyloxy]-2'-hydroxychalcone 
• 1209470-19-8 7-[2-(benzyloxy)benzyloxy]-5-hydroxyflavanone 
• 106419-92-5 2-[2-(benzyloxy)benzyl]-1,3-propanediol 
• 106419-88-9 diethyl 2-(2-(benzyloxy)benzyl)malonate 

Relevant articles and documents

Solvent responsive catalyst improves NMR sensitivity: Via efficient magnetisation transfer

A bidentate iridium carbene complex, Ir(κC,O-L1)(COD), has been synthesised which contains a strongly electron donating carbene ligand that is functionalised by a cis-spanning phenolate group. This complex acts as a precursor to effective magne

Highly Active Multidentate Ligand-Based Alkyne Metathesis Catalysts

Alkyne metathesis catalysts composed of molybdenum(VI) propylidyne and multidentate tris(2-hydroxylbenzyl)methane ligands have been developed, which exhibit excellent stability (remains active in solution for months at room temperature), high activity, an

Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists

Aim: Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. Methods: Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. Results: A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. Conclusion: 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Amino acids derived benzoxazepines: Design, synthesis and antitumor activity

Two series of new benzoxazepines substituted with different alkyl amino ethyl chains were synthesized comprising synthetic steps of inter and intramolecular Mitsunobu reaction, lithium aluminium hydride (LAH) reduction, debenzylation, bimolecular nucleophilic substitution (SN2) reaction. The present study investigates the effect of a tyrosine-based benzoxazepine derivative in human breast cancer cells MCF-7 and MDA-MB-231 and in breast cancer animal model. The anti-proliferative effect of 15a on MCF-7 cells was associated with G1 cell-cycle arrest. This G1 growth arrest was followed by apoptosis as 15a dose dependently increased phosphatidylserine exposure, PARP cleavage and DNA fragmentation that are hallmarks of apoptotic cell death. Interestingly, 15a activated components of both intrinsic and extrinsic pathways of apoptosis characterized by activation of caspase-8 and -9, mitochondrial membrane depolarization and increase in Bax/Bcl2 ratio. However, use of selective caspase inhibitors revealed that the caspase-8-dependent pathway is the major contributor to 15a-induced apoptosis. Compound 15a also significantly reduced the growth of MCF-7 xenograft tumors in athymic nude mice. Together, 15a could serve as a base for the development of a new group of effective breast cancer therapeutics.

Use of the cascade α-oxo-amidoalkylation/transposition/π-cationic cyclization of N-acyliminium ions in the synthesis of novel fused heterocyclic N,O-acetals

Tricyclic N,O-acetal scaffolds have been prepared easily in few steps starting from cheap reagents in moderate to good yields (40-68%) in which the α-hydroxy lactam intermediates constitute the key substrates. These cyclized products are the result of the

Acidic rearrangement of (benzyloxy)chalcones: A short synthesis of chamanetin

Treatment of (benzyloxy)chalcones with trifluoroacetic acid in refluxing chloroform gave several new benzyl(hydroxy)flavanones in high yields and good regioselectivities. By using this procedure, we prepared the natural compound chamanetin in good yield from readily available reagents. Georg Thieme Verlag Stuttgart - New York.

Antibacterial Agents

The invention provides compounds of formula (I) and salts thereof: R1-L-R2—B wherein R1, L, R2, and B have any of the values defined herein, as well as compositions comprising such compounds, and therapeutic methods comprising the administration of such compounds or salts. The compounds block siderophore production in bacteria and are useful as antibacterial agents.

Rationally-designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis

A rationally designed nucleoside inhibitor of Mycobacterium tuberculosis growth (MIC99 = 0.19 μM) that disrupts siderophore biosynthesis was identified. The activity is due to inhibition of the adenylate-forming enzyme MbtA which is involved in

Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelators

Novel 3-hydroxypyridin-4-one containing tridentate ligands were synthesised and their physicochemical properties characterised, including ionisation constants and stoichiometric titration with Fe(III). There is an urgent demand for orally active iron chelators with potential for the treatment of thalassaemia. In principle, tridentate ligands are likely to be more kinetically stable than bidentate molecules, but to date no satisfactory molecules have been identified. Fe(III) stability constants were assessed by competition with the hexadentate ligand EDTA. In all cases no evidence was found for a tridentate mode of iron chelation; instead the ligands behaved as bidentate hydroxypyridinones. As a consequence they provide no advantage over the more simple alkyl hydroxypyridinones.

A bibenzyl from Empetrum nigrum

A new bibenzyl, 1-(2-hydroxyphenyl)-2-(3-hydroxy-4,5-dimethoxyphenyl)- ethane, possessing similar germination inhibitory activity to batatasin III in vitro, was isolated from the leaves of Empetrum nigrum. The isolation, structural determination and synth